A patient with chronic kidney disease and an elevated BUN of 36 mg/dL but a normal eGFR (≥90 mL/min/1.73 m²) – what CKD stage does he belong to?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 2, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

CKD Staging with Elevated BUN but Normal eGFR

A patient with chronic kidney disease, elevated BUN (36 mg/dL), and normal eGFR (≥90 mL/min/1.73 m²) can only be classified as CKD Stage 1 if there is documented evidence of kidney damage—most commonly albuminuria (UACR ≥30 mg/g)—persisting for at least 3 months; without such evidence, the patient does not meet criteria for any CKD stage. 1

Understanding the Diagnostic Criteria

CKD Stages 1 and 2 require two components:

  • Normal or mildly reduced eGFR (Stage 1: ≥90 mL/min/1.73 m²; Stage 2: 60-89 mL/min/1.73 m²) 1
  • AND documented evidence of kidney damage 1

CKD Stages 3-5 are defined by eGFR alone:

  • Stage 3a: eGFR 45-59 mL/min/1.73 m² 1
  • Stage 3b: eGFR 30-44 mL/min/1.73 m² 1, 2
  • Stage 4: eGFR 15-29 mL/min/1.73 m² 1
  • Stage 5: eGFR <15 mL/min/1.73 m² 1, 3

Why BUN Alone Is Insufficient

Elevated BUN without reduced eGFR does not establish CKD because:

  • BUN is influenced by multiple non-renal factors including dietary protein intake, gastrointestinal bleeding, catabolic states, dehydration, and certain medications 4
  • Serum creatinine and calculated eGFR provide far more reliable assessment of actual kidney function than BUN 5, 6
  • The BUN-to-creatinine ratio helps distinguish prerenal azotemia from intrinsic kidney disease, but neither BUN nor this ratio alone defines CKD stage 4

Required Evidence of Kidney Damage for Stage 1 CKD

To diagnose CKD Stage 1 with normal eGFR, you must document at least one of the following persisting ≥3 months: 1

  • Albuminuria: UACR ≥30 mg/g on random spot urine (preferred method) 1, 7
  • Pathological abnormalities: Kidney biopsy showing glomerulonephritis, interstitial nephritis, or other structural disease 1
  • Imaging abnormalities: Polycystic kidneys, hydronephrosis, cortical scarring, or asymmetric kidney size on ultrasound or CT 1
  • Glomerular hematuria: Dysmorphic red blood cells or red cell casts on urinalysis 1

Immediate Next Steps

Measure urinary albumin-to-creatinine ratio (UACR) on a random spot urine sample immediately to determine whether kidney damage is present. 1, 7

If UACR ≥30 mg/g:

  • Repeat UACR measurement within 3-6 months to confirm persistence (two of three specimens should be abnormal due to biological variability) 1
  • Once confirmed, the patient has CKD Stage 1 1
  • Initiate annual monitoring of both eGFR and UACR 7
  • Evaluate and treat underlying causes (diabetes, hypertension) 1

If UACR <30 mg/g and no other markers of kidney damage:

  • The patient does not have CKD by current classification 1
  • The elevated BUN likely reflects prerenal factors (dehydration, high protein intake, GI bleeding) or increased catabolism 4
  • Address reversible causes of elevated BUN 4

Common Pitfall to Avoid

Never diagnose CKD based on elevated BUN or serum creatinine alone without calculating eGFR using validated equations (MDRD or CKD-EPI). Serum creatinine can remain within the "normal" reference range despite loss of 50% or more of kidney function, particularly in elderly or low-muscle-mass patients. 5, 6 Similarly, BUN elevation without eGFR reduction or albuminuria does not establish chronic kidney disease. 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Stage 3b Chronic Kidney Disease (CKD) – Evidence‑Based Management Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

CKD Stage 5 and ESRF Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Chronic Kidney Disease And Associated Risk Factors Among Cardiovascular Patients.

International journal of nephrology and renovascular disease, 2019

Guideline

Chronic Kidney Disease Causes and Risk Factors

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What investigations and management are recommended for a 50‑year‑old woman with newly diagnosed chronic kidney disease (serum creatinine 1.45 mg/dL, eGFR ≈55 mL/min/1.73 m²) and ultrasound showing loss of corticomedullary differentiation with increased cortical echogenicity?
What is the recommended management for a patient with chronic kidney disease stage 3 (eGFR 30–59 mL/min/1.73 m²)?
What is the eGFR of a 51-year-old male with a creatinine level of 15.1 mg/dL?
What does an eGFR of 91.1 indicate about kidney function?
What is the appropriate treatment for hypocalcemia in a patient with stage 3 chronic kidney disease (creatinine ≈ 1.46 mg/dL, estimated glomerular filtration rate ≈ 49 mL/min/1.73 m²)?
How should I manage a patient with atrial fibrillation, heart rate 57 bpm, who is taking apixaban (Eliquis)?
In a 23‑year‑old woman on day 3 of a second 7‑day course of nitrofurantoin (Macrobid) for uncomplicated cystitis who develops fever and chills, now afebrile with borderline hypotension and tachycardia and a negative urine analysis, what is the appropriate next step in management?
What is the safest and most commonly used anxiolytic, with recommended dosing, for patients with acute coronary syndrome?
What is the recommended treatment for mild vascular congestion using Bumex (bumetanide)?
In a patient with end‑stage renal disease who has a markedly elevated parathyroid hormone level and low calcium, what is the most likely cause and how should it be managed?
What follow‑up plan should be implemented for an 84‑year‑old woman with a surgery‑provoked deep‑vein thrombosis and pulmonary embolism after hip fracture repair (open‑reduction internal fixation), who is now on apixaban (Eliquis) 5 mg twice daily and was on a therapeutic heparin infusion during hospitalization?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.